Peninsula Pharmaceutical’s lead product, doripenem, was approved by the FDA in 2007 – about two years after Peninsula was acquired by Johnson & Johnson for approximately $250 million. At the time of that transaction, Peninsula had initiated six Phase 3 clinical trials with doripenem, a broad-spectrum antibiotic aimed at treating hospital-acquired pneumonia, complicated urinary tract infection and other intra-abdominal infections.